WARSAW, Poland, Dec. 5, 2022 /PRNewswire/ -- Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, announces agenda topics and participating key opinion leaders for its virtual R&D Day. The webcast event will be hosted by Molecure on the 7th December 2022 at 13.30 - 16.30 CET / 12.30 – 15.30 BST/ 7.30 – 10.30 ET.
The meeting is available here:
https://us06web.zoom.us/j/84261604213?pwd=QTlVZytQTWFUd3Y1N080R2hwWGZydz09
The presentations by Key Opinion Leaders and Molecure management will showcase the scientific insights and clear clinical needs that underpin Molecure's pipeline programs. Molecure's Vision, Strategy and Pipeline
Clinical evaluation in sarcoidosis and potential patient impact (Prof. Krenke) Clinical development plan
State of oncology in Poland (Prof. Szczylik) Clinical development plan
Key Opinion Leader Presenters:
Prof. Cezary Szczylik, Oncologist, Head of the Department of Clinical Oncology and Chemotherapy Europejskie Centrum Zdrowia (European Health Center) Otwock
Dr Marcin Szumowski - CEO, President of the Board
Dr Zbigniew Zasłona - VP Research Biology, Member of the Board
Dr Samson Fung - Chief Medical Officer
Dr Nicolas Beuzen - Director of Business Development and Licensing
For further information, please contact:
MEDiSTRAVA Consulting (Financial PR)
Frazer Hall, David Dible, Sandi Greenwood, Eleanor Perkin
Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of underexplored protein and RNA targets to treat multiple incurable diseases. Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer. Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in Łódź. The company is listed on the Warsaw Stock Exchange (ticker: MOC).
For more information, please visit www.molecure.com